
Neuphoria Therapeutics fell 47.2% from $4.70 to $2.48, behind the S&P 500's +11.2%. Its worst day was Jul 1 (−18.8%), and its low came Nov 16 at $2.48.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Neuphoria Therapeutics shares fell 8.5%, while the S&P 500 rose 0.7%.
−8.5% · S&P 500 +0.7%
EPS of $-0.77 missed the $-0.56 estimate on $0.00 revenue.
+8.9% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.09 beat the $-0.56 estimate on $0.00 revenue.
−7.3% · S&P 500 −1.2%
Neuphoria Therapeutics shares fell 18.8%, while the S&P 500 fell 0.1%.
−18.8%, the year's worst day · S&P 500 −0.1%
Neuphoria Therapeutics shares rose 17.7%, while the S&P 500 fell 1.2%.
+17.7%, the year's best day, on 8M shares, the year's heaviest volume · S&P 500 −1.2%
EPS of $-0.95 missed the $-0.56 estimate on $1.2M revenue.
+0.3% · S&P 500 +1.6%
Neuphoria Therapeutics shares fell 8.9%, while the S&P 500 fell 0.4%.
−8.9% · S&P 500 −0.4%
Where it ended: a close of $2.48 on Nov 16, 2026. Up next: Q1 2027 earnings on Dec 1, 2026 (EPS est. $-0.42).
Nothing in the past 12 months.
All NEUP dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NEUP and SPY from Benzinga historical bars. Not investment advice.